Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer

The prognosis of patients with unresectable or recurrent pancreatic cancers is very poor. Prior to development of nab-paclitaxel (PTX) plus gemcitabine (GEM) therapy and FOLFIRINOX therapy, there was no recommended third-line chemotherapy after 5-fluorouracil (5-FU) and GEM-based regimens. The prese...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2018-04, Vol.8 (4), p.523-527
Main Authors: Wu, Qi-Bing, Sheng, Xin, Zhang, Ning, Yang, Ming-Wei, Wang, Fan
Format: Article
Language:English
Subjects:
Anorexia
Antigens
Cancer therapies
Cell cycle
Chemotherapy
Development and progression
Disease
Drug dosages
Drug therapy
Fibroblasts
Medical prognosis
Methods
Neutropenia
Oncology
Paclitaxel
Palliative care
Pancreatic cancer
Patient outcomes
Patients
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis of patients with unresectable or recurrent pancreatic cancers is very poor. Prior to development of nab-paclitaxel (PTX) plus gemcitabine (GEM) therapy and FOLFIRINOX therapy, there was no recommended third-line chemotherapy after 5-fluorouracil (5-FU) and GEM-based regimens. The present study conducted a Phase I clinical trial of weekly low-dose PTX as a third-line palliative chemotherapy for patients with pancreatic cancer. PTX was administered on days 1, 8, 15, and 22 of each cycle, repeated twice as follows: Level 1, 40 mg/m (n=6); Level 2, 50 mg/m (n=4). During the two cycles, three patients developed Grade 3 neutropenia in level 2; thus, the recommended dose was defined as 40 mg/m . The disease control rate was 40.0% (stable disease, n=4). Median time to treatment failure of the four patients with stable disease was 5.5 months. In conclusion, palliative chemotherapy with low-dose PTX after failure of GEM and 5-FU is well tolerated and safe for unresectable or recurrent pancreatic cancer patients. The unique ID issues by UMIN: 000008148.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2018.1579